

# EVALUATION OF LUMINEX<sup>®</sup> NxTAG<sup>™</sup> RESPIRATORY PATHOGEN PANEL (RPP) ON NASOPHARYNGEAL SWABS



Chong S<sup>1</sup>, Gonsalves S<sup>2</sup>, Axford M<sup>2</sup>, Yip C<sup>2</sup>, Dey C<sup>2</sup>, Zhang HW<sup>2</sup>, and Mahony J<sup>1</sup>

<sup>1</sup>Department of Pathology and Molecular Medicine, McMaster University, St. Joseph's Healthcare, Hamilton, ON, Canada

<sup>2</sup>Luminex Corporation, Toronto, ON, Canada



## INTRODUCTION

The Luminex NxTAG<sup>™</sup> Respiratory Pathogen Panel (RPP) is a qualitative nucleic acid multiplex test that provides simultaneous detection and identification of 19 viruses and 3 atypical bacteria associated with respiratory tract infections. NxTAG RPP is a ready to use system requiring very little hands-on time and is performed in a closed PCR vessel, reducing the chances of contamination. Nucleic acid is simply added directly to pre-plated lyophilized reagents for RT-PCR and bead hybridization. Results are read on the MAGPIX<sup>®</sup> instrument. The objective of this study is to evaluate the performance of the prototype NxTAG RPP assay currently in development for nasopharyngeal swabs.

## MATERIALS AND METHODS

**Specimens:** Anonymized remnants of 345 nasopharyngeal specimens submitted to the Regional Virology Laboratory at St. Joseph's Healthcare (Hamilton, Canada) between January to March 2013, were used in this study.

**Nucleic Acid Extraction:** 200 µl of nasopharyngeal swab spiked with 10 µl of MS2 bacteriophage was extracted for total nucleic acid in an elution volume of 110 µl using the easyMAG<sup>®</sup> extractor (bioMérieux, St. Laurent, Canada).

**NxTAG RPP Testing:** The prototype NxTAG RPP assay, a qualitative multiplex test that provides simultaneous detection and identification of multiple viral and atypical bacterial pathogens causing respiratory infections (Table 1), was performed as per manufacturer's instructions (Figure 1).


**Table 1: Pathogens Detected in the NxTAG RPP Assay**

	Pathogens
Virus	Influenza A Influenza A subtypes (H1, 2009 H1N1, H3) Influenza B Respiratory Syncytial Virus A and B Parainfluenza 1 to 4 Coronavirus 229E Coronavirus NL63 Coronavirus OC43 Coronavirus HKU-1 Human Metapneumovirus Rhinovirus/Enterovirus Adenovirus Bocavirus
Atypical Bacteria	<i>Chlamydomphila pneumoniae</i> <i>Legionella pneumophila</i> <i>Mycoplasma pneumoniae</i>

For Research Use Only. Not for use in diagnostic procedures.

## MATERIALS AND METHOD

**Figure 1: Workflow of the NxTAG RPP Assay**



**Reference Testing:** All specimens were tested for Adenovirus, Parainfluenza 1 to 3, Influenza A, Influenza B, Respiratory Syncytial Virus and Human Metapneumovirus by a well-characterized RT-PCR test. Specimens that yielded a positive call in the NxTAG RPP for a pathogen not assessed by the RT-PCR, were confirmed by bi-directional sequencing and/or xTAG<sup>®</sup> Respiratory Viral Panel (RVP).

## RESULTS

**Table 2: General Demographic Details for the Specimen Set (N=345)**

Sex	Number of Subjects
Male	179
Female	166
Age (years)	
0-5	105
6-17	19
≥18	221

**Table 3: NxTAG RPP Positivity Rates for Various Pathogens**

Pathogen	Positivity Rate
Influenza A	33/345 (9.6%)
Influenza A 2009 H1N1	10/345 (2.9%)
Influenza A H3	22/345 (6.4%)
Influenza B	6/345 (1.7%)
RSV A	34/345 (9.9%)
RSV B	33/345 (9.6%)
Parainfluenza 2	1/345 (0.3%)
Parainfluenza 3	7/345 (2.0%)
Parainfluenza 4	1/345 (0.3%)
Coronavirus NL63	4/345 (1.2%)
Coronavirus OC43	4/345 (1.2%)
Metapneumovirus	28/345 (8.1%)
Rhinovirus	26/345 (7.5%)
Adenovirus	2/345 (0.6%)

- Overall positive agreement between the NxTAG RPP and the RT-PCR for the common viruses was 99.3% (138/139) (Table 4). Overall negative agreement in this comparison was 99.8% (2960/2966).
- There were 29 specimens positive in the NxTAG RPP assay for viruses not assessed in the RT-PCR. The positive and negative agreement between the NxTAG RPP and bi-directional sequencing or xTAG<sup>®</sup> RVP for these additional viruses was 96.7% and 99.7%, respectively (Table 5).

## RESULTS

**Table 4: Positive and Negative Agreement between NxTAG RPP and RT-PCR**

Pathogen	Positive Agreement		Negative Agreement	
	TP/TP + FN	%	TN/TN + FP	%
Adenovirus	2/2	100.0	343/343	100.0
Influenza A	31/31	100.0	312/314	99.4
Influenza B	6/6	100.0	339/339	100.0
Metapneumovirus	27/28	96.4	316/317	99.7
Parainfluenza 1	0/0	NA	345/345	100.0
Parainfluenza 2	0/0	NA	344/345	99.7
Parainfluenza 3	6/6	100.0	338/339	99.7
RSV A	33/33	100.0	311/312	99.7
RSV B	33/33	100.0	312/312	100.0
<b>TOTAL</b>	<b>138/139</b>	<b>99.3</b>	<b>2960/2966</b>	<b>99.8</b>

**Table 5: Positive and Negative Agreement between NxTAG RPP and Bi-Directional Sequencing or xTAG RVP**

Pathogen	Positive Agreement		Negative Agreement	
	TP/TP + FN	%	TN/TN + FP	%
Parainfluenza 4	0/1	0	343/344	99.7
Coronavirus 229E	0/0	NA	345/345	100.0
Coronavirus HKU-1	0/0	NA	345/345	100.0
Coronavirus NL63	4/4	100.0	341/341	100.0
Coronavirus OC43	2/2	100.0	341/343	99.4
Rhinovirus	23/23	100.0	319/322	99.1
<b>TOTAL</b>	<b>29/30</b>	<b>96.7</b>	<b>2034/2040</b>	<b>99.7</b>

## CONCLUSIONS

- In a study of 345 nasopharyngeal swabs specimens, the prototype NxTAG RPP assay showed a combined positive and negative agreement to RT-PCR, bi-directional sequencing or xTAG RVP of 98.8% (167/169) and 99.8% (4994/5006), respectively.
- Multiplexed RT-PCR and bead hybridization of the NxTAG RPP assay occurs in a closed PCR vessel. There is no post PCR transfer steps, reducing the possibility of contamination. The assay requires very little hands-on time and enables batch processing of up to 192 samples within 8 hours.
- Further studies are required to evaluate the performance of the NxTAG RPP for the lower prevalent viruses and the atypical bacterial pathogens.